| Revenue Growth | Global revenue $127.3M (+30%); US $95.3M; International $32M. |
|---|---|
| Mgmt Confidence | High confidence in Vyjuvek's long-term growth and intrinsic stock value. |
| Demand Visibility | Strong demand with 760+ US reimbursement approvals and 80 new prescribers. |
| Margin Trends | Gross margin 94%, down from 96% due to international launch costs. |
| Op. Leverage | Growing commercial business funding global expansion and R&D pipeline internally. |
| Pricing Power | Secured pricing in Japan, Germany, and Italy; Spain decision expected year-end. |
| Vol vs Price | Growth driven by expanding prescriber network and international market entries. |
| Segment Growth | International revenue reached $32M; US remains primary driver at $95.3M. |
| New Clients | Added 80 new US prescribers; 20+ centers active in Germany. |
| Capex & Debt | $1.2B cash; $400M share repurchase authorized over next two years. |
| Regulatory | Engaging FDA on KB113; complex innovative design meeting for CF program. |
| Commentary | Focusing on disciplined capital allocation between R&D and returning shareholder capital. |
| New Launches | Italy launch expected early 2027; Spain launch potential in 2025. |
Growth
Total revenue reached $127.3 million, up 30% YoY; US revenue contributed $95.3 million.
Outlook
Expects Italy launch in early 2027 and multiple clinical readouts throughout 2027.
Risks
Management pivoted on specific enrollment numbers for NK and CF trials, citing stringent criteria and delays.
The company's earnings call, NASDAQ: KRYS, and its 8-K filed with the SEC. Summary written with AI assistance from the call.
Earnings call webcast ↗ Watch on YouTube ↗
Krystal Biotech, Inc.: key numbers
- Share price
- $297.90Close, Nov 16
- Market cap
- $8.83B
- Shares outstanding
- 29.63MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Krystal Biotech, Inc.
All →Krystal Biotech Financial Results
Krystal Biotech reported third quarter 2026 financial results, highlighted by $127.3 million in global VYJUVEK net product revenue, a 30% year-over-year increase. The company ended the quarter with a strong cash position of $1.2 billion and announced a new $400 million share repurchase program. Additionally, the company completed pricing negotiations for VYJUVEK in Germany and Italy and reported positive clinical data for its KB113 candidate in Gorlin syndrome.
“Continued growth in VYJUVEK revenue is supporting profitability and funding the advancement of our pipeline. Our financial strength allows us to invest fully in these programs and our global commercial expansion while returning capital to shareholders. The $400 million share repurchase program, under which we expect to repurchase shares opportunistically over the next two years, reflects our confidence in Krystal’s long-term growth prospects and our commitment to disciplined capital allocation.”
Krish S. Krishnan, Chairman and Chief Executive Officer
Krystal Biotech Q3 2026 Results: Net Income $63.1M, Down 20.5% YoY
Krystal Biotech reported a strong third quarter in 2026, with product revenue increasing to $127.3 million compared to $97.8 million in the prior year. Net income for the nine months ended September 30, 2026, rose to $173.8 million, supported by significant growth in cash and investments totaling over $1.19 billion.
- Key figure
- Net income $63.1M · -20.5% YoY
Krystal Biotech Clinical Trial Data
Krystal Biotech announced positive proof-of-concept clinical data from its Gorlin Syndrome Pilot Study evaluating KB113 for the treatment of basal cell carcinomas. The study showed that over 80% of assessed lesions regressed across three patients, including non-injected lesions, suggesting a systemic abscopal effect.